Evotec SE ADR Earnings

The next earnings date for Evotec SE ADR is November 5, 2025.

They are scheduled to announce earnings after the market closes that day.

Analyst Estimates of Evotec SE ADR Earnings

Report DateEstimated Earnings Per Share
11/05/2025$-0.05

What is an Earnings Date

An earnings date is typically considered to be the date that a company publicly announces its earnings. Many companies in the US stock market do earnings announcements once per quarter.

Earnings announcements are typically accompanied by commentary from the company that explains the earnings performance and speaks to future earnings prospects.

Earnings announcements can cause a company’s stock price to change abruptly, so earnings dates are closely monitored by some investors.

Evotec SE ADR Earnings: Historical

Report DateBefore/After MarketEarnings Per ShareSurprise %
08/13/2025---$-0.12-79.91%
06/10/2025Before Market$-0.12-2.25%
11/06/2024Before Market$-0.12-50.00%
08/14/2024Before Market$-0.29-380.33%
05/22/2024Before Market$-0.0640.00%
02/26/2024Before Market$-0.05-66.67%
11/08/2023Before Market$-0.12-140.00%
08/29/2023Before Market$-0.040.00%
05/12/2023After Market$-0.08-180.00%
03/29/2023Before Market$-0.13-230.00%
11/10/2022---$-0.140.00%
08/11/2022After Market$-0.08-366.67%
05/11/2022Before Market$-0.23-483.33%
11/11/2021Before Market$1.88---
08/11/2021---$0.88---
05/11/2021Before Market$0.77---
03/25/2021Before Market$0.00---
11/12/2020Before Market$-0.02---
08/12/2020Before Market$-0.14---
05/14/2020Before Market$0.25---
03/26/2020Before Market$0.12---
11/12/2019---$0.07---
08/14/2019---$-0.01---
05/14/2019---$0.05---
11/13/2018Before Market$0.55---
08/09/2018Before Market$0.23---
05/09/2018Before Market$0.06---
03/28/2018Before Market$0.16---
11/08/2017Before Market$0.05---
08/10/2017Before Market$0.05---
05/10/2017Before Market$0.11---
03/28/2017---$0.06---
11/10/2016---$0.04---
08/10/2016---$0.02---
05/10/2016---$-0.00---
03/22/2016---$0.02---
11/10/2015---$-0.01---
08/12/2015---$0.06---
05/12/2015---$-0.00---
03/24/2015---$0.00---
11/12/2014Before Market$-0.07---
08/12/2014Before Market$-0.01---
05/14/2014Before Market$-0.08---
03/25/2014Before Market$-0.46---
11/12/2013Before Market$-0.01---
08/08/2013Before Market$-0.04---
05/14/2013---$-0.02---
03/26/2013---$-0.03---
11/08/2012---$0.03---
08/08/2012---$0.02---
05/10/2012---$-0.01---
03/20/2012---$-0.01---
11/10/2011---$0.05---
08/11/2011---$0.01---
05/12/2011---$-0.00---
03/24/2011---$0.01---
11/11/2010---$0.01---
08/12/2010---$0.01---
05/12/2010---$-0.01---
03/25/2010---$-0.08---
11/12/2009---$-0.02---
08/07/2009---$-0.06---
05/12/2009---$-0.13---
03/27/2009---$-0.34---
11/14/2008---$-0.02---
08/06/2008---$-0.10---
05/08/2008---$-0.14---
08/14/2007---$-0.12---
05/10/2007---$0.03---
03/29/2007---$-0.16---
11/09/2006---$-0.05---
08/11/2006---$-0.01---
05/11/2006---$-0.10---
11/09/2005---$-0.07---
08/11/2005---$-0.33---
05/10/2005---$-0.08---
03/22/2005---$-1.19---
11/11/2004---$-0.10---
08/11/2004---$-0.09---
05/12/2004---$-0.11---

More About Evotec SE ADR

Website
https://www.evotec.com
Country
USA
Full Time Employees
4,759

Evotec SE operates as a drug discovery and development company in the United States, Germany, France, the United Kingdom, Switzerland, and internationally. It operates in two segments, Shared R&D and Just " Evotec Biologics. The company is developing pharmaceutical products in various therapeutic areas, such as oncology, autoimmune, cancer, diabetes, heart failure, immunology, pain and inflammation, infectious, kidney, liver, respiratory, fibrotic and metabolic disease, and rare diseases; central nervous system (CNS) and cardiometabolic diseases; and animal and women health. The company has collaboration agreements with Mass General Brigham and Joslin Diabetes Center focusing on cardiometabolic diseases; BMS antiviral; Novo Nordisk cell therapy; University of Oxford; German Cancer Research Center; University Hospital in Hamburg; University of Toronto, Harvard, and Yale; Johns Hopkins University; Ospedale San Raffaele (OSR); and National University of Singapore. It has a partnership with LAB282, LAB150, beLAB2122, beLAB1407, LAB eN², Danube Labs, VC Amplitude Ventures, LaB eN2, and 65LAB. The company serves pharma and biotechnology companies, academic institutions, patient advocacy groups, and venture capital. The company was formerly known as Evotec AG and changed its name to Evotec SE in April 2019. Evotec SE was incorporated in 1993 and is headquartered in Hamburg, Germany.

“Evotec SE ADR Earnings” Can Refer to the Evotec SE ADR Earnings Date

Some people say “Evotec SE ADR earnings” as a shortform way to refer to the earnings date.

For example, someone might say, “I plan to hold my Evotec SE ADR position through earnings.” That typically means the person is going to hold their position through the upcoming earnings date.

Owning Evotec SE ADR Stock on the Earnings Date

If you own Evotec SE ADR stock (EVO) on the earnings date, then you will be exposed to the potential price volatility that often accompanies earnings announcements.

A company’s earnings typically have a big impact on its stock price, which explains why the stock price for Evotec SE ADR might exhibit major fluctuations on the day of the earnings announcement. The price fluctuations can go in either direction (up or down), representing a larger potential investment risk and reward than many other days of the year.

There is often a big audience of investors involved with trading Evotec SE ADR shares of stock on its earnings day. This means there is typically more trading volume, liquidity, and price volatility on the day earnings are announced.

These features are attractive to some types of active traders who are looking for stocks that exhibit large price movements and substantial volume.

Learning More Evotec SE ADR Earnings

You can contact us any time if you would like to ask questions about Evotec SE ADR earnings or anything else related to the stock market.

This site uses cookies to provide you with an optimal user experience. By using StockMarketGuides.com, you accept our use of cookies.